Novartis | NOVN - Cash And Equivalent

Stock Price
119.98
Daily Change
0.70 0.59%
Monthly
5.62%
Yearly
23.91%
Q1 Forecast
111.83

Novartis reported $9.56B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Alcon AG USD 1.5B 90M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Autolus Therapeutics Ltd USD 86.12M 37.7M Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Fresenius EUR 1.23B 1.16B Jun/2025
Fresenius Medical Care EUR 1.26B 459.13M Sep/2025
Galapagos EUR 64.46M 43.61M Sep/2025
Genmab DKK 1.3B 323M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
J&J USD 18.23B 10.35B Sep/2025
Lonza CHF 1.11B 286M Dec/2024
Merck EUR 1.17B 161M Jun/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Orion EUR 224.2M 35.2M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Philips EUR 1.91B 90M Sep/2025
Recordati EUR 341.55M 8.51M Jun/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024